Brokerages Set Aktis Oncology (NASDAQ:AKTS) Price Target at $34.60

Shares of Aktis Oncology (NASDAQ:AKTS) have been assigned an average rating of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $34.60.

A number of equities analysts recently issued reports on the stock. Wall Street Zen lowered shares of Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. JPMorgan Chase & Co. boosted their price target on shares of Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th. Raymond James Financial initiated coverage on shares of Aktis Oncology in a report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price objective for the company. HC Wainwright raised their price objective on shares of Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. Finally, William Blair initiated coverage on Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating on the stock.

Aktis Oncology Price Performance

Shares of AKTS stock opened at $24.00 on Thursday. Aktis Oncology has a 12-month low of $14.72 and a 12-month high of $34.19. The firm has a market capitalization of $1.28 billion and a price-to-earnings ratio of -63.16. The business has a 50 day simple moving average of $24.79 and a 200 day simple moving average of $21.11.

Aktis Oncology (NASDAQ:AKTS) last announced its earnings results on Monday, May 11th. The technology company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.01). The business had revenue of $3.23 million during the quarter, compared to analysts’ expectations of $2.23 million. On average, equities analysts anticipate that Aktis Oncology will post -1.64 EPS for the current fiscal year.

Insider Activity

In other news, Director Ken Herrmann sold 4,856 shares of the business’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $24.56, for a total value of $119,263.36. Following the sale, the director owned 3,506 shares of the company’s stock, valued at approximately $86,107.36. The trade was a 58.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AKTS. BlackRock Inc. lifted its holdings in Aktis Oncology by 7.9% in the 2nd quarter. BlackRock Inc. now owns 2,278,358 shares of the technology company’s stock valued at $73,431,000 after acquiring an additional 166,231 shares during the last quarter. Deutsche Bank AG boosted its holdings in Aktis Oncology by 49.3% during the second quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock worth $678,000 after buying an additional 6,942 shares in the last quarter. Bank of New York Mellon Corp grew its position in Aktis Oncology by 14.8% in the second quarter. Bank of New York Mellon Corp now owns 49,250 shares of the technology company’s stock worth $1,587,000 after buying an additional 6,349 shares during the last quarter. State of Wyoming acquired a new position in Aktis Oncology in the second quarter worth approximately $32,000. Finally, Great Lakes Advisors LLC bought a new position in shares of Aktis Oncology in the second quarter valued at $1,406,000. 28.84% of the stock is owned by institutional investors and hedge funds.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.